 | • レポートコード：MRC309Z8038 • 出版社/出版日：GlobalInfoResearch / 2023年9月20日 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界のロピバカインメシル酸塩の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界のロピバカインメシル酸塩市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - ロピバカインメシル酸塩の成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため ロピバカインメシル酸塩市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・2 mg/mL (0.2%)、5 mg/mL (0.5%)、7.5 mg/mL (0.75%)、10 mg/mL (1%) 用途別セグメント ・外科麻酔、主要神経ブロック、急性疼痛管理、その他 主要な市場プレーヤー ・Pfizer、Akorn、Anant Pharmaceuticals、SGPharma、Nephron Pharmaceuticals、Sintetica SA、AstraZeneca、Manus Aktteva Biopharma LLP、Zhejiang Xianju Pharmaceutical Co.,Ltd、Jiangsu Nhwa Pharmaceutical Co.,Ltd.、Yangzi River Pharmaceutical Group、Jiangsu Hengrui Pharmaceuticals Co., Ltd.、Jiangsu Nhwa Pharmaceutical Co.,Ltd 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、ロピバカインメシル酸塩製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なロピバカインメシル酸塩メーカーの企業概要、2019年～2022年までのロピバカインメシル酸塩の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なロピバカインメシル酸塩メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別ロピバカインメシル酸塩の販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までのロピバカインメシル酸塩の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのロピバカインメシル酸塩市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、およびロピバカインメシル酸塩の産業チェーンを掲載しています。 ・第14、15章では、ロピバカインメシル酸塩の販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - ロピバカインメシル酸塩の概要 - 種類別分析（2018年vs2022年vs2029年）：2 mg/mL (0.2%)、5 mg/mL (0.5%)、7.5 mg/mL (0.75%)、10 mg/mL (1%) - 用途別分析（2018年vs2022年vs2029年）：外科麻酔、主要神経ブロック、急性疼痛管理、その他 - 世界のロピバカインメシル酸塩市場規模・予測 - 世界のロピバカインメシル酸塩生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Pfizer、Akorn、Anant Pharmaceuticals、SGPharma、Nephron Pharmaceuticals、Sintetica SA、AstraZeneca、Manus Aktteva Biopharma LLP、Zhejiang Xianju Pharmaceutical Co.,Ltd、Jiangsu Nhwa Pharmaceutical Co.,Ltd.、Yangzi River Pharmaceutical Group、Jiangsu Hengrui Pharmaceuticals Co., Ltd.、Jiangsu Nhwa Pharmaceutical Co.,Ltd ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：2 mg/mL (0.2%)、5 mg/mL (0.5%)、7.5 mg/mL (0.75%)、10 mg/mL (1%) ・用途別分析2018年-2029年：外科麻酔、主要神経ブロック、急性疼痛管理、その他 ・ロピバカインメシル酸塩の北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・ロピバカインメシル酸塩のヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・ロピバカインメシル酸塩のアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・ロピバカインメシル酸塩の南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・ロピバカインメシル酸塩の中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Ropivacaine Mesylate market size was valued at USD 895.2 million in 2022 and is forecast to a readjusted size of USD 1357.2 million by 2029 with a CAGR of 6.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup.
This report is a detailed and comprehensive analysis for global Ropivacaine Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Ropivacaine Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Ropivacaine Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Ropivacaine Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Ropivacaine Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Ropivacaine Mesylate
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Ropivacaine Mesylate market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Akorn, Anant Pharmaceuticals, SGPharma and Nephron Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Ropivacaine Mesylate market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2 mg/mL (0.2%)
5 mg/mL (0.5%)
7.5 mg/mL (0.75%)
10 mg/mL (1%)
Market segment by Application
Surgical Anesthesia
Major Nerve Block
Acute Pain Management
Other
Major players covered
Pfizer
Akorn
Anant Pharmaceuticals
SGPharma
Nephron Pharmaceuticals
Sintetica SA
AstraZeneca
Manus Aktteva Biopharma LLP
Zhejiang Xianju Pharmaceutical Co.,Ltd
Jiangsu Nhwa Pharmaceutical Co.,Ltd.
Yangzi River Pharmaceutical Group
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co.,Ltd
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Ropivacaine Mesylate product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Ropivacaine Mesylate, with price, sales, revenue and global market share of Ropivacaine Mesylate from 2018 to 2023.
Chapter 3, the Ropivacaine Mesylate competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ropivacaine Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Ropivacaine Mesylate market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Ropivacaine Mesylate.
Chapter 14 and 15, to describe Ropivacaine Mesylate sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Ropivacaine Mesylate
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Ropivacaine Mesylate Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 2 mg/mL (0.2%)
1.3.3 5 mg/mL (0.5%)
1.3.4 7.5 mg/mL (0.75%)
1.3.5 10 mg/mL (1%)
1.4 Market Analysis by Application
1.4.1 Overview: Global Ropivacaine Mesylate Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Surgical Anesthesia
1.4.3 Major Nerve Block
1.4.4 Acute Pain Management
1.4.5 Other
1.5 Global Ropivacaine Mesylate Market Size & Forecast
1.5.1 Global Ropivacaine Mesylate Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Ropivacaine Mesylate Sales Quantity (2018-2029)
1.5.3 Global Ropivacaine Mesylate Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Ropivacaine Mesylate Product and Services
2.1.4 Pfizer Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Akorn
2.2.1 Akorn Details
2.2.2 Akorn Major Business
2.2.3 Akorn Ropivacaine Mesylate Product and Services
2.2.4 Akorn Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Akorn Recent Developments/Updates
2.3 Anant Pharmaceuticals
2.3.1 Anant Pharmaceuticals Details
2.3.2 Anant Pharmaceuticals Major Business
2.3.3 Anant Pharmaceuticals Ropivacaine Mesylate Product and Services
2.3.4 Anant Pharmaceuticals Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Anant Pharmaceuticals Recent Developments/Updates
2.4 SGPharma
2.4.1 SGPharma Details
2.4.2 SGPharma Major Business
2.4.3 SGPharma Ropivacaine Mesylate Product and Services
2.4.4 SGPharma Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 SGPharma Recent Developments/Updates
2.5 Nephron Pharmaceuticals
2.5.1 Nephron Pharmaceuticals Details
2.5.2 Nephron Pharmaceuticals Major Business
2.5.3 Nephron Pharmaceuticals Ropivacaine Mesylate Product and Services
2.5.4 Nephron Pharmaceuticals Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Nephron Pharmaceuticals Recent Developments/Updates
2.6 Sintetica SA
2.6.1 Sintetica SA Details
2.6.2 Sintetica SA Major Business
2.6.3 Sintetica SA Ropivacaine Mesylate Product and Services
2.6.4 Sintetica SA Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Sintetica SA Recent Developments/Updates
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Ropivacaine Mesylate Product and Services
2.7.4 AstraZeneca Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AstraZeneca Recent Developments/Updates
2.8 Manus Aktteva Biopharma LLP
2.8.1 Manus Aktteva Biopharma LLP Details
2.8.2 Manus Aktteva Biopharma LLP Major Business
2.8.3 Manus Aktteva Biopharma LLP Ropivacaine Mesylate Product and Services
2.8.4 Manus Aktteva Biopharma LLP Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Manus Aktteva Biopharma LLP Recent Developments/Updates
2.9 Zhejiang Xianju Pharmaceutical Co.,Ltd
2.9.1 Zhejiang Xianju Pharmaceutical Co.,Ltd Details
2.9.2 Zhejiang Xianju Pharmaceutical Co.,Ltd Major Business
2.9.3 Zhejiang Xianju Pharmaceutical Co.,Ltd Ropivacaine Mesylate Product and Services
2.9.4 Zhejiang Xianju Pharmaceutical Co.,Ltd Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Zhejiang Xianju Pharmaceutical Co.,Ltd Recent Developments/Updates
2.10 Jiangsu Nhwa Pharmaceutical Co.,Ltd.
2.10.1 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Details
2.10.2 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Major Business
2.10.3 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Ropivacaine Mesylate Product and Services
2.10.4 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Jiangsu Nhwa Pharmaceutical Co.,Ltd. Recent Developments/Updates
2.11 Yangzi River Pharmaceutical Group
2.11.1 Yangzi River Pharmaceutical Group Details
2.11.2 Yangzi River Pharmaceutical Group Major Business
2.11.3 Yangzi River Pharmaceutical Group Ropivacaine Mesylate Product and Services
2.11.4 Yangzi River Pharmaceutical Group Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Yangzi River Pharmaceutical Group Recent Developments/Updates
2.12 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
2.12.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
2.12.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
2.12.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ropivacaine Mesylate Product and Services
2.12.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
2.13 Jiangsu Nhwa Pharmaceutical Co.,Ltd
2.13.1 Jiangsu Nhwa Pharmaceutical Co.,Ltd Details
2.13.2 Jiangsu Nhwa Pharmaceutical Co.,Ltd Major Business
2.13.3 Jiangsu Nhwa Pharmaceutical Co.,Ltd Ropivacaine Mesylate Product and Services
2.13.4 Jiangsu Nhwa Pharmaceutical Co.,Ltd Ropivacaine Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Jiangsu Nhwa Pharmaceutical Co.,Ltd Recent Developments/Updates
3 Competitive Environment: Ropivacaine Mesylate by Manufacturer
3.1 Global Ropivacaine Mesylate Sales Quantity by Manufacturer (2018-2023)
3.2 Global Ropivacaine Mesylate Revenue by Manufacturer (2018-2023)
3.3 Global Ropivacaine Mesylate Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Ropivacaine Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Ropivacaine Mesylate Manufacturer Market Share in 2022
3.4.2 Top 6 Ropivacaine Mesylate Manufacturer Market Share in 2022
3.5 Ropivacaine Mesylate Market: Overall Company Footprint Analysis
3.5.1 Ropivacaine Mesylate Market: Region Footprint
3.5.2 Ropivacaine Mesylate Market: Company Product Type Footprint
3.5.3 Ropivacaine Mesylate Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Ropivacaine Mesylate Market Size by Region
4.1.1 Global Ropivacaine Mesylate Sales Quantity by Region (2018-2029)
4.1.2 Global Ropivacaine Mesylate Consumption Value by Region (2018-2029)
4.1.3 Global Ropivacaine Mesylate Average Price by Region (2018-2029)
4.2 North America Ropivacaine Mesylate Consumption Value (2018-2029)
4.3 Europe Ropivacaine Mesylate Consumption Value (2018-2029)
4.4 Asia-Pacific Ropivacaine Mesylate Consumption Value (2018-2029)
4.5 South America Ropivacaine Mesylate Consumption Value (2018-2029)
4.6 Middle East and Africa Ropivacaine Mesylate Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
5.2 Global Ropivacaine Mesylate Consumption Value by Type (2018-2029)
5.3 Global Ropivacaine Mesylate Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
6.2 Global Ropivacaine Mesylate Consumption Value by Application (2018-2029)
6.3 Global Ropivacaine Mesylate Average Price by Application (2018-2029)
7 North America
7.1 North America Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
7.2 North America Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
7.3 North America Ropivacaine Mesylate Market Size by Country
7.3.1 North America Ropivacaine Mesylate Sales Quantity by Country (2018-2029)
7.3.2 North America Ropivacaine Mesylate Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
8.2 Europe Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
8.3 Europe Ropivacaine Mesylate Market Size by Country
8.3.1 Europe Ropivacaine Mesylate Sales Quantity by Country (2018-2029)
8.3.2 Europe Ropivacaine Mesylate Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Ropivacaine Mesylate Market Size by Region
9.3.1 Asia-Pacific Ropivacaine Mesylate Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Ropivacaine Mesylate Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
10.2 South America Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
10.3 South America Ropivacaine Mesylate Market Size by Country
10.3.1 South America Ropivacaine Mesylate Sales Quantity by Country (2018-2029)
10.3.2 South America Ropivacaine Mesylate Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Ropivacaine Mesylate Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Ropivacaine Mesylate Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Ropivacaine Mesylate Market Size by Country
11.3.1 Middle East & Africa Ropivacaine Mesylate Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Ropivacaine Mesylate Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Ropivacaine Mesylate Market Drivers
12.2 Ropivacaine Mesylate Market Restraints
12.3 Ropivacaine Mesylate Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Ropivacaine Mesylate and Key Manufacturers
13.2 Manufacturing Costs Percentage of Ropivacaine Mesylate
13.3 Ropivacaine Mesylate Production Process
13.4 Ropivacaine Mesylate Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Ropivacaine Mesylate Typical Distributors
14.3 Ropivacaine Mesylate Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer